• NASDAQ:VXRT adds 0.67% on Thursday amidst a mostly flat trading session in the global markets.
  • Investors await news on Vaxart’s latest clinical studies for its COVID-19 treatment candidate.
  • Logistical issues and allergic reactions may open the door for Vaxart’s unique treatment.

NASDAQ:VXRT was little changed on Thursday despite the first official FDA approvals for the COVID-19 vaccine candidate from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Vaxart added 0.67% during Thursday’s trading session as the stock closed the day at $7.46, which represents a gain of over 80% during the last month as investors begin to speculate on the next group of companies who could receive regulatory approval. 

The results of Vacart’s Phase 1 clinical studies for its treatment VXA-CoV2-1 should be ready by January and Phase 2 should follow closely after if the findings are positive. What sets Vaxart’s treatment candidate apart that investors are so excited about? It is an oral pill and not a shot, which of course makes storage and shipment around the world a logistical dream compared to vaccines that need to be stored in below-freezing containers. The oral pill could also have fewer side effects as the first round of COVID-19 vaccine shots have already returned some allergic reactions. Manufacturing of pills should be much simpler than the production of vaccine samples as well, meaning potential lower costs and wider availability to all corners of the world. 

Vaxart stock news

VRXT stock price chart

Needless to say, the stock has had a pretty good run since entering the race for a COVID-19 treatment earlier this year. Shares have returned over 2,300% and at a reasonable price level, investors could look to Vaxart as an appealing play in the next wave of COVID-19 treatment options. Investing in biotechs can be risky, but investors should keep a close eye on the clinical trial results as the low price of this stock could lead to some massive gains down the road. 

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Feed news Join Telegram

Recommended content


Recommended content

Editors’ Picks

AUD/USD extends rally above 0.6800 as US Dollar sell-off continues

AUD/USD extends rally above 0.6800 as US Dollar sell-off continues

The AUD/USD pair trades near a weekly peak of 0.6843, maintaining the bullish potential intact amid US data supporting a slower pace of quantitative tightening. Focus now on RBA’s Governor Lowe speech.

AUDUSD News

EUR/USD holds on to gains at around 1.0510

EUR/USD holds on to gains at around 1.0510

EUR/USD holds on to substantial gains above 1.0500 amid the broad US Dollar weakness. Optimism further fueled the rally as China moves away from its zero-Covid policy.

EUR/USD News

Gold bulls conquered $1,800, what’s next?

Gold bulls conquered $1,800, what’s next?

Gold jumped to $1,804.00, its highest since early August. The metal benefited from an extended USD sell-off as US macroeconomic figures fueled Powell’s triggered slump. On Wednesday, the Dollar fell on the back of a dovish message from Fed's Powell.

Gold News

Bitcoin price witnesses 44% increase of deposits to all exchanges in November

Bitcoin price witnesses 44% increase of deposits to all exchanges in November

BTC rallied back into the $17,000 price zone after several failed attempts. Bitcoin price a countertrend move just before November's auction finalized. Still, on-chain metrics suggest the downtrend is not yet over.

Read more

Nonfarm Payrolls Preview: Dollar selling opportunity? Low expectations to trigger temporary bounce Premium

Nonfarm Payrolls Preview: Dollar selling opportunity? Low expectations to trigger temporary bounce

A flashback to 2019 just before 2022 ends? The last Nonfarm Payrolls release is set to show a pre-pandemic level of job gains, around 200,000. Or maybe lower. However, expect another positive surprise – triggering a temporary Dollar bounce. 

Read more

Forex MAJORS

Cryptocurrencies

Signatures